187 related articles for article (PubMed ID: 24981574)
1. Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways.
Chiang KC; Tsui KH; Chung LC; Yeh CN; Feng TH; Chen WT; Chang PL; Chiang HY; Juang HH
Sci Rep; 2014 Jul; 4():5511. PubMed ID: 24981574
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells.
Chiang KC; Tsui KH; Chung LC; Yeh CN; Chang PL; Chen WT; Juang HH
PLoS One; 2014; 9(2):e89117. PubMed ID: 24586533
[TBL] [Abstract][Full Text] [Related]
3. L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells.
Chung LC; Tsui KH; Feng TH; Lee SL; Chang PL; Juang HH
Am J Physiol Cell Physiol; 2012 Feb; 302(4):C676-85. PubMed ID: 22116304
[TBL] [Abstract][Full Text] [Related]
4. Triiodothyronine modulates cell proliferation of human prostatic carcinoma cells by downregulation of the B-cell translocation gene 2.
Tsui KH; Hsieh WC; Lin MH; Chang PL; Juang HH
Prostate; 2008 May; 68(6):610-9. PubMed ID: 18196550
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of prostate-derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells.
Tsui KH; Chung LC; Feng TH; Chang PL; Juang HH
Int J Cancer; 2012 Jun; 130(12):2812-23. PubMed ID: 21780100
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative B cell translocation gene 2 protein is down-regulated post-transcriptionally as an early event in prostate carcinogenesis.
Ficazzola MA; Fraiman M; Gitlin J; Woo K; Melamed J; Rubin MA; Walden PD
Carcinogenesis; 2001 Aug; 22(8):1271-9. PubMed ID: 11470758
[TBL] [Abstract][Full Text] [Related]
7. BTG2 is an LXXLL-dependent co-repressor for androgen receptor transcriptional activity.
Hu XD; Meng QH; Xu JY; Jiao Y; Ge CM; Jacob A; Wang P; Rosen EM; Fan S
Biochem Biophys Res Commun; 2011 Jan; 404(4):903-9. PubMed ID: 21172304
[TBL] [Abstract][Full Text] [Related]
8. BTG2 is a tumor suppressor gene upregulated by p53 and PTEN in human bladder carcinoma cells.
Tsui KH; Chiang KC; Lin YH; Chang KS; Feng TH; Juang HH
Cancer Med; 2018 Jan; 7(1):184-195. PubMed ID: 29239139
[TBL] [Abstract][Full Text] [Related]
9. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer.
Jalava SE; Urbanucci A; Latonen L; Waltering KK; Sahu B; Jänne OA; Seppälä J; Lähdesmäki H; Tammela TL; Visakorpi T
Oncogene; 2012 Oct; 31(41):4460-71. PubMed ID: 22266859
[TBL] [Abstract][Full Text] [Related]
10. Activation of p53 signaling and inhibition of androgen receptor mediate tanshinone IIA induced G1 arrest in LNCaP prostate cancer cells.
Won SH; Lee HJ; Jeong SJ; Lü J; Kim SH
Phytother Res; 2012 May; 26(5):669-74. PubMed ID: 21997969
[TBL] [Abstract][Full Text] [Related]
11. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition.
Coppola V; Musumeci M; Patrizii M; Cannistraci A; Addario A; Maugeri-Saccà M; Biffoni M; Francescangeli F; Cordenonsi M; Piccolo S; Memeo L; Pagliuca A; Muto G; Zeuner A; De Maria R; Bonci D
Oncogene; 2013 Apr; 32(14):1843-53. PubMed ID: 22614007
[TBL] [Abstract][Full Text] [Related]
12. Starvation-induced activation of ATM/Chk2/p53 signaling sensitizes cancer cells to cisplatin.
Shi Y; Felley-Bosco E; Marti TM; Orlowski K; Pruschy M; Stahel RA
BMC Cancer; 2012 Dec; 12():571. PubMed ID: 23211021
[TBL] [Abstract][Full Text] [Related]
13. [Effect of compound Chinese traditional medicine PC-SPES II in inhibiting proliferation of human prostate cancer cell LNCaP and on expressions of AR and PSA].
Zhang BY; Li YF; Lai Y; Li YS; Chen ZJ
Zhongguo Zhong Yao Za Zhi; 2015 Mar; 40(5):950-6. PubMed ID: 26087562
[TBL] [Abstract][Full Text] [Related]
14. Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells.
Tsui KH; Chang YL; Feng TH; Hou CP; Lin YH; Yang PS; Lee BW; Juang HH
Prostate; 2018 Mar; 78(4):242-249. PubMed ID: 29164633
[TBL] [Abstract][Full Text] [Related]
15. Growth hormone (GH) receptors in prostate cancer: gene expression in human tissues and cell lines and characterization, GH signaling and androgen receptor regulation in LNCaP cells.
Weiss-Messer E; Merom O; Adi A; Karry R; Bidosee M; Ber R; Kaploun A; Stein A; Barkey RJ
Mol Cell Endocrinol; 2004 May; 220(1-2):109-23. PubMed ID: 15196705
[TBL] [Abstract][Full Text] [Related]
16. Diverse effects of ANXA7 and p53 on LNCaP prostate cancer cells are associated with regulation of SGK1 transcription and phosphorylation of the SGK1 target FOXO3A.
Srivastava M; Leighton X; Starr J; Eidelman O; Pollard HB
Biomed Res Int; 2014; 2014():193635. PubMed ID: 24864229
[TBL] [Abstract][Full Text] [Related]
17. Regulation of Btg2(/TIS21/PC3) expression via reactive oxygen species-protein kinase C-ΝFκΒ pathway under stress conditions.
Imran M; Lim IK
Cell Signal; 2013 Dec; 25(12):2400-12. PubMed ID: 23876794
[TBL] [Abstract][Full Text] [Related]
18. Grape seed extract induces anoikis and caspase-mediated apoptosis in human prostate carcinoma LNCaP cells: possible role of ataxia telangiectasia mutated-p53 activation.
Kaur M; Agarwal R; Agarwal C
Mol Cancer Ther; 2006 May; 5(5):1265-74. PubMed ID: 16731759
[TBL] [Abstract][Full Text] [Related]
19. The Combination of Metformin and Valproic Acid Induces Synergistic Apoptosis in the Presence of p53 and Androgen Signaling in Prostate Cancer.
Tran LNK; Kichenadasse G; Butler LM; Centenera MM; Morel KL; Ormsby RJ; Michael MZ; Lower KM; Sykes PJ
Mol Cancer Ther; 2017 Dec; 16(12):2689-2700. PubMed ID: 28802253
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway.
Li X; Li T; Chen D; Zhang P; Song Y; Zhu H; Xiao Y; Xing Y
Oncol Rep; 2016 Jan; 35(1):584-92. PubMed ID: 26534764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]